title: Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat.
abstract: Improved biomarkers of acute nephrotoxicity are coveted by the drug development industry, regulatory agencies, and clinicians. In an effort to identify such biomarkers, urinary peptide profiles of rats treated with two different nephrotoxins were investigated. 493 marker candidates were defined that showed a significant response to cis-platin comparing a cis-platin treated cohort to controls. Next, urine samples from rats that received three consecutive daily doses of 150 or 300 mg/kg gentamicin were examined. 557 potential biomarkers were initially identified; 108 of these gentamicin-response markers showed a clear temporal response to treatment. 39 of the cisplatin-response markers also displayed a clear response to gentamicin. Of the combined 147 peptides, 101 were similarly regulated by gentamicin or cis-platin and 54 could be identified by tandem mass spectrometry. Most were collagen type I and type III fragments up-regulated in response to gentamicin treatment. Based on these peptides, classification models were generated and validated in a longitudinal study. In agreement with histopathology, the observed changes in classification scores were transient, initiated after the first dose, and generally persistent over a period of 10-20 days before returning to control levels. The data support the hypothesis that gentamicin-induced renal toxicity up-regulates protease activity, resulting in an increase in several specific urinary collagen fragments. Urinary proteomic biomarkers identified here, especially those common to both nephrotoxins, may serve as a valuable tool to investigate potential new drug candidates for the risk of nephrotoxicity.
authors.affiliation: Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America. rodney.rouse@fda.hhs.gov
authors.forename: Rodney
authors.initials: R
authors.lastname: Rouse
authors.forename: Justyna
authors.initials: J
authors.lastname: Siwy
authors.forename: William
authors.initials: W
authors.lastname: Mullen
authors.forename: Harald
authors.initials: H
authors.lastname: Mischak
authors.forename: Jochen
authors.initials: J
authors.lastname: Metzger
authors.forename: Joseph
authors.initials: J
authors.lastname: Hanig
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000652:urine; D002945:Cisplatin / Q000633:toxicity; D005839:Gentamicins / Q000633:toxicity; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism*; D010455:Peptides / Q000652:urine; D020543:Proteome / Q000032:analysis / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D051381:Rats; D023382:Toxicity Tests, Acute / Q000379:methods*
chemical_list: D015415:Biomarkers; D005839:Gentamicins; D010455:Peptides; D020543:Proteome; D002945:Cisplatin